The Latest Cardiac and Vascular News
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities. “The second quarter of 2022 marked […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten offering of 5,950,000 American Depositary Shares (“ADSs”), each representing three […]
Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate […]
— Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate primary efficacy analysis; topline data readout for RAPID study remains on track for mid-second half 2022 — Phase 3 PSVT study initiated in China MONTREAL and CHARLOTTE, N.C., Aug. 10, 2022 /PRNewswire/ — Milestone Pharmaceuticals […]
New CEO Appointed, Manufacturing Progress Noted TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and six months […]
Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company […]
SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2022 and filed its quarterly report on Form 10-Q for the three and six months ended […]
WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its underwritten public offering, which was upsized to an aggregate […]
Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022. The Company will host a webcast and conference call at […]
Provides Additional Working Capital to Further Fund Growth Initiatives SILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (the “Company”), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corporation. The new credit facility […]
